BioPharmSignal logoBioPharmSignal

Biotech News

Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification

Genenta Science (GNTA)Genenta ScienceCompany update

MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) (the “Company”) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not

Related news

GNTAGenenta Science2026-11-02 11:00 EST

Genenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial Platform

KURAKura Oncology2026-11-06 12:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-10-19 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Genenta Science

Genenta Science is a cell-therapy company focused on engineered myeloid cells and cancer immunotherapy. Its platform aims to create a new class of cellular medicine for oncology.

Recent company news

GNTAGenenta Science2026-11-02 11:00 EST

Genenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial Platform

GNTAGenenta Science2026-10-21 20:01 EST

Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification

GNTAGenenta Science2026-09-15 08:10 EST

Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit

GNTAGenenta Science2026-07-23 07:09 EST

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

GNTAGenenta Science2026-07-22 08:00 EST

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

Stock data

Close
0.99 USD
Market cap
51.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States